Thursday 16 October, 2025
Objectives: PVR (CD155) and CD112 are two ligands from the Nectin/Nectin-like family which are frequently expressed on different types of…
Read morePoster: Drug/Disease Modelling - Oncology
Population Pharmacokinetic and Exposure-Efficacy/Safety Analyses for the Confirmation of Alectinib 600 mg BID Dose Regimen in the Global ALK Inhibitor-Naïve Population
Thursday 16 October, 2025
Introduction: Alectinib is a tyrosine kinase inhibitor that targets Anaplastic Lymphoma Kinase (ALK) and REarranged during Transfection (RET), thereby inhibiting…
Read moreExtension of population pharmacokinetic analysis of pembrolizumab to paediatric patients patients with classical Hodgkin lymphoma
Thursday 16 October, 2025
Introduction: Pembrolizumab is globally approved in adults with various solid tumor as well as hematological cancer indications. To date, it…
Read morePopulation Pharmacokinetic and Exposure Response Analysis of Belzutifan in Advanced Renal Cell Carcinoma
Thursday 16 October, 2025
Objectives: A previously developed population pharmacokinetic (PopPK) model for belzutifan based on data from patients with VHL disease [1] was…
Read moreUnveiling a “predator/prey” interplay of anti-CD19 CAR T-Cells and their targets in Relapsed/refractory DLBCL patients
Thursday 16 October, 2025
Objectives: CD19-targeted Chimeric Antigen Receptor (CAR) T-cells are recombinant receptors for CD19 antigen that redirect patients’ T lymphocytes toward CD19+ cell…
Read moreA multi drug disposition model accounting for rituximab antigen binding portion (Fab) and crystallizable (Fc) mediated drug disposition mechanisms
Thursday 16 October, 2025
Objectives: Rituximab, an anti-CD20 monoclonal antibody, has been approved in several diseases involving CD19+ B cells, including non-Hodgking lymphoma (NHL), chronic…
Read moreInfluence of immunization on the pharmacokinetics of monoclonal antibodies : anti-drug antibody-mediated drug disposition (ADAMDD) of rituximab in mice
Thursday 16 October, 2025
Introduction: Immunisation against monoclonal antibodies (mAbs) lead to the development of anti-drug antibodies (ADA) that are responsible of an increase…
Read morePKPD modeling of preclinical anti-tumor activity translates to first-in-human phase I study of MDM2 inhibitor HDM201
Thursday 16 October, 2025
Objectives: The purpose of this work was to investigate the predictability from preclinical to clinical of a model-based analysis capturing…
Read moreA Population Pharmacokinetic Analysis to Explore the Effect of Hepatic Impairment on Abemaciclib Pharmacokinetics
Thursday 16 October, 2025
Objectives: Abemaciclib, a potent inhibitor of CDK4&6 for treatment of HR+ HER2- locally advanced or metastatic breast cancer [1,2,3], is…
Read morePopulation pharmacokinetic modeling and bioequivalence clinical trial simulations of niraparib plus abiraterone acetate administered as single-agent combination and dual-acting tablets plus prednisone for the treatment of metastatic castration-resistant prostate cancer
Thursday 16 October, 2025
Objectives: The combination of niraparib and abiraterone acetate (AA), a prodrug of abiraterone, targets two oncogenic drivers in patients with…
Read more